Back to top

Analyst Blog

Astellas Pharma, Inc. (ALPMY) and FibroGen Inc., a privately-held biotechnology company, recently commenced a phase II study in Japan on ASP1517/FG-4592.

ASP1517/FG-4592 is being studied for the treatment of anemia associated with chronic kidney disease (CKD) in patients on dialysis. On the initiation of the study, FibroGen received a $12.5 million milestone payment from Astellas.

In late 2013, Astellas will conduct an additional phase II study in Japan on the candidate in non-dialysis patients.

Astellas had licensed certain rights to ASP1517/FG-4592 from FibroGen in Japan, Europe, the Commonwealth of Independent States (CIS), the Middle East, and South Africa. Under this deal, both the companies will equally share development costs for the candidate in the U.S. and Europe. Astellas will solely bear the development costs in Japan. Milestone payments will be made on the achievement of clinical milestones and approvals in Japan and Europe.

The first phase III study on ASP1517/FG-4592 commenced in Dec 2012. Data from the study is expected to support approval of the candidate in the U.S. and Europe.

As per information provided by Astellas, CKD is a global healthcare problem affecting more than 10% of the global population. The incidence of the disease is on the rise.

We note that the market for the treatment of anemia associated with CKD includes drugs such as AMAG Pharmaceuticals, Inc.’s (AMAG - Snapshot Report) Feraheme.

Astellas carries a Zacks Rank #3 (Hold). Currently, companies like Questcor Pharmaceuticals Inc. and Anika Therapeutics Inc.   look well-positioned with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SOUTHWEST A… LUV 31.94 +2.24%
CHINA BIOLO… CBPO 47.40 +2.20%
MALLINCKROD… MNK 72.35 +2.02%
PLANAR SYST… PLNR 4.30 +1.78%
GILEAD SCIE… GILD 103.86 +1.55%